Elsevier Announces the Launch of New Open Access Journal, Schizophrenia Research: Cognition
New York, March 27, 2014
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of Schizophrenia Research: Cognition, a new open access journal dedicated to publishing original research, concise research reports, brief reports, letters to the editor, and review papers addressing the role of cognitive functioning in schizophrenia.
As a spin-off from companion journal Schizophrenia Research, which is one of the most recognized journals in the field, Schizophrenia Research: Cognition specializes in providing a forum on all aspects of cognition in schizophrenia, including clinical neuropsychology, neurocognition, social cognition, functional capacity, cognitive and social neuroscience, and aspects of everyday outcome as related to cognition. Articles that compare the influence of cognition and other influences on outcome in schizophrenia will also be published as will research on descriptive characteristics, genetic influences, pharmacological and non-pharmacological treatments, and neuroimaging correlates of these aspects of cognition.
Schizophrenia Research: Cognition is an online-only journal and articles will be published rapidly after acceptance. The journal will publish the latest developments in the field, which currently are too often scattered among a host of other journals that do not always prominently feature these articles. Schizophrenia Research: Cognition will bring together research from other scientific disciplines including, neuroscience, genomics, and psychiatry.
Dr. Philip D. Harvey, Editor-in-Chief of Schizophrenia Research: Cognition, explained, “The benefits of an international, specialized open-access journal focusing on cognition in schizophrenia will include broadening access to the rapidly changing developments in the field to scientists with limited access to subscription journals.”
Published articles are now available on ScienceDirect and www.SchizResCognition.com
For more information or to submit an article, go to:
www.SchizResCognition.com or www.elsevier.com/journals/schizophrenia-research-cognition/2215-0013
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+44 20 7424 4404